Piper Sandler raises Intuitive Surgical stock price target on strong Q2

Intuitive Surgical (ISRG) reported a robust Q2 2025, surpassing analyst expectations with revenue of $2.44 billion and EPS of $2.19, alongside an impressive 38.8% operating margin and 17% procedure volume growth. This strong performance led management to raise full-year 2025 procedure guidance to 15.5-17% and prompted Piper Sandler and Baird to increase their price targets, maintaining positive ratings. The company's recent commercial approval for its DV5 system in Japan and Europe further underpins its accelerating growth trajectory.

Analysis

Intuitive Surgical (ISRG) delivered a robust second-quarter performance, exceeding consensus expectations with revenue of $2.44 billion and EPS of $2.19, representing a significant 13.47% earnings surprise. This top-and-bottom-line beat was driven by strong operational execution, highlighted by a 17% year-over-year growth in procedure volumes and an impressive operating margin of 38.8%, substantially higher than the 34.6% consensus. Global system placements remained solid at 395 units, nearly matching forecasts. In response to this momentum, management has raised its full-year 2025 procedure growth guidance to a range of 15.5-17%. The positive outlook is further supported by recent commercial approvals for its next-generation DV5 system in Japan and Europe, a key catalyst for future growth. The strong results have prompted bullish analyst revisions, with Piper Sandler and Baird raising their price targets to $595 and $600, respectively, while maintaining Overweight/Outperform ratings. Despite these strong fundamentals and a 'GREAT' financial health score from InvestingPro, the stock is noted to be trading at a premium to its fair value.

Key Decisions for Investors

• Given the significant earnings beat, raised guidance, and new product cycle with the DV5 system, investors may view any price weakness as a long-term buying opportunity for this market leader in surgical robotics.
• Investors should monitor the adoption rate of the new DV5 system in Europe and Japan, as well as continued procedure volume growth, as these are the primary catalysts supporting the company's premium valuation.
• Despite the strong performance, the stock's premium valuation warrants caution; investors should weigh the clear operational momentum against the potential for valuation-driven volatility in the near term.